NASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Price, News & Analysis → Elon Musk: “This Could be Massive…a Multi Trillion-Dollar Company.” (From Paradigm Press) (Ad) Free SRPT Stock Alerts $158.00 +0.04 (+0.03%) (As of 06/28/2024 ET) Add Compare Share Share Today's Range$156.00▼$159.7750-Day Range$113.33▼$163.8552-Week Range$55.25▼$173.25Volume1.93 million shsAverage Volume3.05 million shsMarket Capitalization$14.93 billionP/E Ratio1,436.36Dividend YieldN/APrice Target$185.06 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Sarepta Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside17.1% Upside$185.06 Price TargetShort InterestBearish10.01% of Shares Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews Sentiment0.32Based on 32 Articles This WeekInsider TradingSelling Shares$8.09 M Sold Last QuarterProj. Earnings Growth141.24%From $3.71 to $8.95 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.36 out of 5 starsMedical Sector120th out of 915 stocksPharmaceutical Preparations Industry41st out of 435 stocks 3.4 Analyst's Opinion Consensus RatingSarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 14 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sarepta Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.01% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Sarepta Therapeutics has recently increased by 45.76%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSarepta Therapeutics has received a 62.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Sarepta Therapeutics is -1.65. Previous Next 3.0 News and Social Media Coverage News SentimentSarepta Therapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 32 news articles for Sarepta Therapeutics this week, compared to 9 articles on an average week.Search Interest37 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 95% compared to the previous 30 days.MarketBeat Follows20 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,086,386.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sarepta Therapeutics' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow by 141.24% in the coming year, from $3.71 to $8.95 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is 1,436.36, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 120.18.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is 1,436.36, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 94.18.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 17.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sarepta Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressElon Musk: “This Could be Massive…a Multi Trillion-Dollar Company.”Have you seen Elon Musk’s latest crazy prediction?Click here to see it because he believes this new venture… About Sarepta Therapeutics Stock (NASDAQ:SRPT)Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Read More SRPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRPT Stock News HeadlinesJune 26, 2024 | insidertrades.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Sells $1,281,645.72 in StockJune 21, 2024 | marketbeat.comSarepta Therapeutics Stock Soars on FDA ApprovalSarepta Therapeutics NASDAQ: SRPT is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics' stock price has witnessed a surge of over 40% after receiving expanded FDA approval for its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys.June 30, 2024 | Paradigm Press (Ad)Elon Musk: “This Could be Massive…a Multi Trillion-Dollar Company.”Have you seen Elon Musk’s latest crazy prediction?June 21, 2024 | marketbeat.comSarepta Therapeutics Stock Soars on FDA ApprovalSarepta Therapeutics' expanded FDA approval for its DMD gene therapy, Elevidys, propels the company into a dominant position in the rare disease market.June 27 at 8:39 AM | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for Sarepta Therapeutics (NASDAQ:SRPT)June 27 at 5:52 AM | americanbankingnews.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Bilal Arif Sells 7,859 SharesJune 27 at 4:38 AM | americanbankingnews.comCitigroup Downgrades Sarepta Therapeutics (NASDAQ:SRPT) to NeutralJune 27 at 1:28 AM | americanbankingnews.comSarepta Therapeutics, Inc. Forecasted to Post Q3 2024 Earnings of $1.92 Per Share (NASDAQ:SRPT)June 30, 2024 | Paradigm Press (Ad)Elon Musk: “This Could be Massive…a Multi Trillion-Dollar Company.”Have you seen Elon Musk’s latest crazy prediction?June 26, 2024 | fool.comIs Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.June 26, 2024 | americanbankingnews.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) EVP Ryan Edward Brown Sells 38,957 SharesJune 26, 2024 | gurufocus.comInsider Sale: EVP, General Counsel Ryan Brown Sells 38,957 Shares of Sarepta Therapeutics Inc (SRPT)June 25, 2024 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $185.00 at Evercore ISIJune 25, 2024 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Increased to $200.00 by Analysts at BMO Capital MarketsJune 25, 2024 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Given New $230.00 Price Target at SVB LeerinkJune 24, 2024 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Sees Unusually-High Trading Volume Following Analyst UpgradeJune 24, 2024 | americanbankingnews.comAnalyzing Sarepta Therapeutics (NASDAQ:SRPT) & ANI Pharmaceuticals (NASDAQ:ANIP)June 23, 2024 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Stock Rating Reaffirmed by Cantor FitzgeraldJune 23, 2024 | americanbankingnews.comPiper Sandler Reiterates Overweight Rating for Sarepta Therapeutics (NASDAQ:SRPT)June 23, 2024 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Reaches New 12-Month High After Analyst UpgradeJune 22, 2024 | seekingalpha.comSarepta Therapeutics: Pushing The Edge And Creating The HorizonJune 22, 2024 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Given New $226.00 Price Target at BarclaysJune 22, 2024 | americanbankingnews.comSarepta Therapeutics' (SRPT) "Overweight" Rating Reaffirmed at Morgan StanleyJune 22, 2024 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $200.00June 22, 2024 | americanbankingnews.comTraders Buy Large Volume of Call Options on Sarepta Therapeutics (NASDAQ:SRPT)June 21, 2024 | seekingalpha.comSarepta Therapeutics: Why Today's Rally On DMD Drug Label Expansion Won't LastJune 21, 2024 | businesswire.comWall Street Beats to Host Conference Call with Sarepta CEO on Ground-Breaking Expanded Label ApprovalSee More Headlines Company Calendar Last Earnings5/01/2024Today6/30/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees1,314Year Founded1980Price Target and Rating Average Stock Price Target$185.06 High Stock Price Target$235.00 Low Stock Price Target$109.00 Potential Upside/Downside+17.1%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$0.11 Trailing P/E Ratio1,436.36 Forward P/E Ratio42.59 P/E GrowthN/ANet Income$-535,980,000.00 Net Margins1.20% Pretax Margin2.43% Return on Equity2.20% Return on Assets0.58% Debt Debt-to-Equity Ratio1.18 Current Ratio4.05 Quick Ratio3.44 Sales & Book Value Annual Sales$1.40 billion Price / Sales10.64 Cash FlowN/A Price / Cash FlowN/A Book Value$9.19 per share Price / Book17.19Miscellaneous Outstanding Shares94,524,000Free Float87,246,000Market Cap$14.93 billion OptionableOptionable Beta0.96 Social Links Key ExecutivesMr. Douglas S. Ingram Esq. (Age 61)President, CEO & Director Comp: $1.62MMr. Ian Michael Estepan (Age 48)Executive VP & CFO Comp: $917.53kDr. Louise R. Rodino-Klapac Ph.D. (Age 46)Executive VP, Chief Scientific Officer and Head of Research & Development Comp: $1.04MMr. Ryan E. Brown J.D. (Age 46)Executive VP, General Counsel & Corporate Secretary Comp: $823.36kMr. Bilal Arif (Age 52)Executive VP & Chief Technical Operations Officer Ms. Francesca T. NolanExecutive Director of Investor Relations and Corporate CommunicationsMs. Alison NasisiExecutive VP & Chief People OfficerDr. Diane L. Berry Ph.D.Executive VP and Chief of Global Policy & Advocacy OfficerMr. Dallan MurrayExecutive VP & Chief Customer OfficerMr. Will TiltonSenior VP, Head of Strategy & Chief of StaffMore ExecutivesKey CompetitorsMirati TherapeuticsNASDAQ:MRTXACADIA PharmaceuticalsNASDAQ:ACADPTC TherapeuticsNASDAQ:PTCTWave Life SciencesNASDAQ:WVESolid BiosciencesNASDAQ:SLDBView All CompetitorsInsiders & InstitutionsRyan Edward BrownSold 38,957 sharesTotal: $6.30 M ($161.61/share)Bilal ArifSold 7,859 sharesTotal: $1.28 M ($163.08/share)Garde Capital Inc.Bought 1,085 shares on 5/29/2024Ownership: 0.001%Farallon Capital Management LLCBought 1,243,427 shares on 5/24/2024Ownership: 2.596%Cetera Investment AdvisersBought 2,590 shares on 5/24/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions SRPT Stock Analysis - Frequently Asked Questions Should I buy or sell Sarepta Therapeutics stock right now? 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SRPT shares. View SRPT analyst ratings or view top-rated stocks. What is Sarepta Therapeutics' stock price target for 2024? 18 brokerages have issued 12-month price objectives for Sarepta Therapeutics' shares. Their SRPT share price targets range from $109.00 to $235.00. On average, they predict the company's stock price to reach $185.06 in the next year. This suggests a possible upside of 17.1% from the stock's current price. View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts. How have SRPT shares performed in 2024? Sarepta Therapeutics' stock was trading at $96.43 on January 1st, 2024. Since then, SRPT shares have increased by 63.8% and is now trading at $158.00. View the best growth stocks for 2024 here. Are investors shorting Sarepta Therapeutics? Sarepta Therapeutics saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 9,460,000 shares, an increase of 45.8% from the May 31st total of 6,490,000 shares. Based on an average daily trading volume, of 1,660,000 shares, the days-to-cover ratio is currently 5.7 days. View Sarepta Therapeutics' Short Interest. When is Sarepta Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our SRPT earnings forecast. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its quarterly earnings data on Wednesday, May, 1st. The biotechnology company reported $0.73 earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.84. The biotechnology company had revenue of $413.50 million for the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a trailing twelve-month return on equity of 2.20% and a net margin of 1.20%. The firm's quarterly revenue was up 63.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.44) earnings per share. What ETFs hold Sarepta Therapeutics' stock? ETFs with the largest weight of Sarepta Therapeutics (NASDAQ:SRPT) stock in their portfolio include Simplify Health Care ETF (PINK), Morningstar US Small Growth (MSGR), iShares Genomics Immunology and Healthcare ETF (IDNA), iShares Neuroscience and Healthcare ETF (IBRN), Global X Genomics & Biotechnology ETF (GNOM), Principal Healthcare Innovators ETF (BTEC), VanEck Biotech ETF (BBH) and Acruence Active Hedge U.S. Equity ETF (XVOL). What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO? 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS). How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Sarepta Therapeutics have any subsidiaries? The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.Read More This page (NASDAQ:SRPT) was last updated on 6/30/2024 by MarketBeat.com Staff From Our PartnersElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Sarepta Therapeutics, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
